Glyxambi

Active Ingredient(s): Empagliflozin + Linagliptin
FDA Approved: * January 30, 2015
Pharm Company: * BOEHRINGER INGELHEIM
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Glyxambi Overview

Empagliflozin/linagliptin is a drug combination used for the treatment of type II diabetes. It is a combination of empagliflozin and linagliptin. The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly under the trade name Glyxambi. Glyxambi was approved for use by the FDA in 2015.[1][2] References ^ Swiatek, Jeff (2 February 2015). "2-in-1 diabetes drug from Eli Lilly and partner OK'd". The Indianapolis Star. Retrie...

Read more Glyxambi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Empagliflozin/linagliptin

Recent Glyxambi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Empagliflozin + Linagliptin
  • Tablet: 10mg + 5mg, 25mg + 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Glyxambi: (2 results)

Sorted by National Drug Code
  • 0597-0164 Glyxambi Oral Tablet, Film Coated by Boehringer Ingelheim Pharmaceuticals, Inc.
  • 0597-0182 Glyxambi Oral Tablet, Film Coated by Boehringer Ingelheim Pharmaceuticals, Inc.

Drugs with one or more similar ingredients: (10 results)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA